Navigation Links
Heyltex Corporation Working With United States and Japan to Add Production of Radiological Antidotes
Date:3/25/2011

rom being taken up by the thyroid gland and promotes its excretion. However, there are numerous other decorporation drugs that have been used for many years for accidents involving radiation workers, and rarely, members of the public. Radiogardase® (Prussian Blue insoluble capsules) helps promote the excretion of radioactive cesium, and sodium and calcium diethylenetriamine pentaacetic acid (DTPA) promotes the excretion of radioactive plutonium.

According to Carol Marcus Ph.D., M.D. Professor of Radiation Oncology and of Radiological Sciences, David Geffen School of Medicine, UCLA "The strategic key to emergency preparedness is to stockpile decorporation drugs in advance. Many decorporation drugs have little or no other medical uses, and are not generally kept in pharmacies and hospitals." Dr. Marcus added, "The companies that manufacture these limited use drugs are consequently small, and have little or no surge capacity to ramp up manufacturing if large quantities are needed. By stockpiling drugs ahead of time, as is done in the United States, we will have a ready supply if they are needed."

"The need for these products to be forward deployed around the world is clear," said Alexander Heyl, CEO of Heyltex Corporation. "Radiogardase is an important part of protecting Americans living near nuclear facilities and a key antidote in protecting against a 'Dirty Bomb' attack involving Cs-137." In addition Mr. Heyl stated that, "The unfortunate incident at Fukushima Daiichi Nuclear Power Facility has put the dangers of radiation exposure on the front page and brought into focus the need for continued planning worldwide."

For more information, visit www.heyltex.com.  


'/>"/>
SOURCE Heyltex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7, 2011 In an address to ... John C. Lechleiter, Ph.D., chairman, president and chief executive ... build a new level of trust between the biopharmaceutical ... can harness innovation to help meet growing health care ...
... 2011 Merit Medical Systems, Inc. (NASDAQ: MMSI ... used primarily in cardiology, radiology and endoscopy, announced today that ... quarter ended June 30, 2011, after the close of the ... will hold its investor conference call on the same day ...
Cached Medicine Technology:Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 2Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 3Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 4
(Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/10/2014)... a new drug could prove useful in treating small cell ... , Scientists from the Cancer Research UK Manchester Institute, based ... Cancer Research Centre, teamed up with experts at AstraZeneca, as ... drug known as AZD3965 - on small cell lung ... Clinical Cancer Research , also helps identify which patients are ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
(Date:7/9/2014)... of low back pain are not linked to weather ... and precipitation. Findings published in Arthritis Care & ... Rheumatology (ACR), indicate that the risk of low back ... gusts, but was not clinically significant. , According ... low back pain at some point in their life, ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2
... in U.S., Canada, study says , FRIDAY, April 16 ... places across the United States and Canada could save ... die of cardiac arrest each year, researchers report. , ... in more limited setting, such as casinos or airports, ...
... Inserting new valve within the valve might help high-risk ... -- If an artificial heart valve derived from a ... implanting a mechanical valve inside the artificial valve could ... and opened, the new valve opens and functions similarly ...
... brain lesions developed in patients taking Lipitor than placebo, ... Cholesterol-lowering statin drugs may slow the progression of multiple ... 81 patients with early-stage MS randomly selected to take ... a placebo. After 12 months of treatment, 55.3 percent ...
... Cardiovascular disease appears to be a major risk factor ... -- People with atrial fibrillation, a form of abnormal heart ... Alzheimer,s disease, a new study finds. , The presence of ... especially among younger patients in the group studied, meaning under ...
... Mo. For seniors, dancing isn,t just for fun; ... by University of Missouri researchers found that participation in ... adults. Improved functionality among seniors can decrease their risk ... as dance-based therapy have the potential to significantly reduce ...
... ... ... Researchers at Drexel University College of Medicine have discovered that a certain type ... critical for cancer growth and movement. When researchers reduced and normalized the levels of this ...
Cached Medicine News:Health News:Public Defibrillators Save Lives 2Health News:Public Defibrillators Save Lives 3Health News:Cholesterol Drugs May Slow MS 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 3Health News:Dance therapy improves seniors' gait, balance, researcher finds 2Health News:Scientists Report Key Finding in Breast Cancer Research 2Health News:Scientists Report Key Finding in Breast Cancer Research 3
Non-Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... disc test (P/N LD15C) include a durable ... instructions. P/N LD15C also includes a Plexiglas ... covers for the test subjects fingers ( ... color discs). Beware that these finger cots ...
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Medicine Products: